Skip Navigation LinksHome > Current Issue > The Biology of Relapsed Acute Lymphoblastic Leukemia: Opport...
Text sizing:
A
A
A
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000179
Invited Review Article

The Biology of Relapsed Acute Lymphoblastic Leukemia: Opportunities for Therapeutic Interventions

Bhatla, Teena MD; Jones, Courtney L. MSc; Meyer, Julia A. PhD; Vitanza, Nicholas A. MD; Raetz, Elizabeth A. MD; Carroll, William L. MD

Collapse Box

Abstract

Although great strides have been made in the improvement of outcome for newly diagnosed pediatric acute lymphoblastic leukemia because of refinements in risk stratification and selective intensification of therapy, the prognosis for relapsed leukemia has lagged behind significantly. Understanding the underlying biological pathways responsible for drug resistance is essential to develop novel approaches for the prevention of recurrence and treatment of relapsed disease. High throughput genomic technologies have the potential to revolutionize cancer care in this era of personalized medicine. Using such advanced technologies, we and others have shown that a diverse assortment of cooperative genetic and epigenetic events drive the resistant phenotype. Herein, we summarize results using a variety of genomic technologies to highlight the power of this methodology in providing insight into the biological mechanisms that impart resistant disease.

Copyright © 2014 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.